TriSalus Life Sciences, Inc.
TLSI
$5.58
-$0.01-0.18%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.17M | 8.26M | 7.35M | 7.36M | 6.46M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.17M | 8.26M | 7.35M | 7.36M | 6.46M |
| Cost of Revenue | 1.50M | 1.22M | 1.00M | 912.00K | 971.00K |
| Gross Profit | 7.67M | 7.05M | 6.35M | 6.45M | 5.49M |
| SG&A Expenses | 11.71M | 13.41M | 9.12M | 9.96M | 11.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.50M | 17.58M | 14.35M | 15.54M | 18.13M |
| Operating Income | -7.33M | -9.32M | -7.00M | -8.17M | -11.67M |
| Income Before Tax | -10.37M | -10.11M | -2.40M | -4.33M | -13.20M |
| Income Tax Expenses | 5.00K | -1.00K | -3.00K | 7.00K | 3.00K |
| Earnings from Continuing Operations | -10.38M | -10.11M | -2.40M | -4.33M | -13.21M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.38M | -10.11M | -2.40M | -4.33M | -13.21M |
| EBIT | -7.33M | -9.32M | -7.00M | -8.17M | -11.67M |
| EBITDA | -7.16M | -9.13M | -6.83M | -7.98M | -11.50M |
| EPS Basic | -0.39 | -0.40 | -0.12 | -0.21 | -0.60 |
| Normalized Basic EPS | -0.21 | -0.25 | -0.07 | -0.47 | -0.25 |
| EPS Diluted | -0.39 | -0.40 | -0.12 | -0.21 | -0.60 |
| Normalized Diluted EPS | -0.21 | -0.25 | -0.07 | -0.47 | -0.25 |
| Average Basic Shares Outstanding | 28.53M | 27.55M | 26.50M | 23.90M | 23.32M |
| Average Diluted Shares Outstanding | 28.53M | 27.55M | 26.50M | 23.90M | 23.32M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |